Supernus Pharmaceuticals Inc. (SUPN)
Here's Why Supernus Pharmaceuticals (SUPN) is a Great Momentum Stock to Buy
Does Supernus Pharmaceuticals (SUPN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Earnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to Decline
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Supernus (SUPN) is Poised to Beat Earnings Estimates Again
Supernus (SUPN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Supernus Pharmaceuticals (SUPN) Is Up 2.81% in One Week: What You Should Know
Does Supernus Pharmaceuticals (SUPN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Supernus Pharmaceuticals, Inc. (SUPN) Hits Fresh High: Is There Still Room to Run?
Supernus (SUPN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Supernus Pharmaceuticals, Inc. (SUPN) Hit a 52 Week High, Can the Run Continue?
Supernus (SUPN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Supernus Pharmaceuticals: Heading In The Right Direction
Supernus Pharmaceuticals shares have rallied nicely after strong 2Q25 results, driven by robust Qelbree and Gocovri sales and a surge in Zurzuvae revenue. Supernus' recent acquisition of Sage Therapeutics added Zurzuvae, the only FDA-approved oral postpartum depression drug, and bolstered the company's balance sheet. Management raised FY25 revenue guidance by 11% and expects continued growth, with analysts forecasting solid EPS and sales through FY27.
Supernus (SUPN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Supernus (SUPN) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Supernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings and Revenue Estimates
Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.47 per share. This compares to earnings of $0.36 per share a year ago.
Supernus Pharmaceuticals, Inc. (SUPN) Q2 2025 Earnings Call Transcript
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Jack A. Khattar - Founder, President, CEO, Secretary & Director Timothy C.
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals (SUPN) Stock?
Investors in Supernus Pharmaceuticals, Inc. SUPN need to pay close attention to the stock based on moves in the options market lately. That is because the June 20, 2025 $30 Call had some of the highest implied volatility of all equity options today.
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2025 Earnings Call Transcript
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Peter Vozzo - Investor Relations-ICR Healthcare Jack Khattar - Chief Executive Officer Tim Dec - Chief Financial Officer Conference Call Participants Stacy Ku - TD Cowen David Amsellem - Piper Sandler Operator Good afternoon and welcome to Supernus Pharmaceuticals First Quarter 2025 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
